AstraZeneca
Some of the key events about AstraZeneca
- 1913The company was founded as Astra AB in Södertälje, Sweden
- 1999Astra AB merged with Zeneca Group to form AstraZeneca
- 1999Paid $355 million to settle allegations of Medicare fraud
- 2003Faced criticism for allegedly suppressing negative clinical trial data for the antidepressant Seroquel
- 2004Launched Crestor, a highly effective cholesterol-lowering drug
- 2007Acquired MedImmune, expanding its biologics and vaccines capabilities
- 2010Paid $520 million to settle allegations of off-label marketing of the antipsychotic drug Seroquel
- 2011Received FDA approval for Brilinta, a blood-thinning medication for acute coronary syndromes
- 2011Agreed to pay $68.5 million to settle allegations of deceptive marketing practices for Seroquel
- 2013Faced accusations of bribing doctors in China to boost drug sales
- 2014Successfully fended off a takeover attempt by Pfizer, maintaining its independence
- 2014Paid $110 million to settle allegations of violating the Foreign Corrupt Practices Act in multiple countries
- 2015Acquired ZS Pharma, strengthening its cardiovascular and metabolic disease portfolio
- 2016Agreed to pay $5.5 million to resolve allegations of violating a previous corporate integrity agreement
- 2019Launched Calquence for the treatment of chronic lymphocytic leukemia
- 2020Developed a COVID-19 vaccine in collaboration with Oxford University
- 2020Faced criticism for delays and supply shortages in COVID-19 vaccine production for the European Union
- 2021Acquired Alexion Pharmaceuticals, expanding into rare disease treatments
- 2021Several European countries temporarily suspended use of AstraZeneca's COVID-19 vaccine due to blood clot concerns
- 2021Criticized for selling its stake in Moderna for $1 billion before the COVID-19 pandemic, missing out on larger gains
Disclaimer: This material is written based on information taken from open sources, including Wikipedia, news media, podcasts, and other public sources.
AstraZeneca Latest news
FTSE 100 Dips as Healthcare and Energy Sectors Struggle, UK Wage Growth Slows
September 10 2024, 04:49 PM • 842 viewsBig Pharma's Vaccine Dilemma: Balancing Profit and Pandemic Preparedness
September 10 2024, 05:17 AM • 705 viewsIndian Shares Poised for Upturn Amid Global Market Rebound
September 10 2024, 02:58 AM • 832 viewsMaryland's Drug Discount Law Survives Legal Challenge from Pharma Giants
September 6 2024, 06:48 PM • 357 viewsJudge Overturns $107.5 Million Verdict in AstraZeneca-Pfizer Patent Dispute
August 14 2024, 07:05 PM • 382 viewsPopular
Blinken Voices Concern Over Escalations Threatening Gaza Cease-fire Talks
• 6172 viewsU.S. Lawmakers Push to Renew Global Fragility Act Amid African Security Concerns
• 6287 viewsKentucky Governor Bans Conversion Therapy for Minors via Executive Order
• 5358 viewsWashington Post Reporter Shifts Focus to Community Impact of D.C. Policies
• 6185 viewsLebanon's Healthcare System Faces Critical Test Amid Ongoing Crises
• 4493 viewsFTSE 100 Dips as Healthcare and Energy Sectors Struggle, UK Wage Growth Slows
London's FTSE 100 fell 0. 8% due to healthcare and energy sector declines. UK wage growth cooled to a two-year low, potentially influencing future Bank of England rate decisions. Precious metal miners saw significant gains.
Big Pharma's Vaccine Dilemma: Balancing Profit and Pandemic Preparedness
Despite COVID-19's impact, pharmaceutical companies are not prioritizing vaccine development for future pandemics. Economic incentives and market volatility pose challenges to long-term preparedness strategies.
Indian Shares Poised for Upturn Amid Global Market Rebound
Indian shares set to open higher, mirroring global market recovery. Investors eye U.S. inflation data and Fed decision, while GST cuts on cancer drugs and snacks draw attention.
Maryland's Drug Discount Law Survives Legal Challenge from Pharma Giants
A federal judge upholds Maryland's law mandating drug discounts for low-income populations, rejecting pharmaceutical companies' bid to block it. This decision impacts the ongoing debate over the 340B program nationwide.
Judge Overturns $107.5 Million Verdict in AstraZeneca-Pfizer Patent Dispute
A federal judge in Delaware has invalidated a jury's decision requiring AstraZeneca to pay Pfizer $107. 5 million for patent infringement. The case centered on AstraZeneca's lung cancer drug Tagrisso.
Global Pharma Giants Eye Chinese Market Despite Geopolitical Tensions
Major pharmaceutical companies are actively seeking acquisitions in China, despite Sino-U. S. tensions. This trend highlights the strategic importance of the Chinese market for global drugmakers.